Media, investors, advocacy organizations and others, please contact us here.

Sparsentan vs Irbesartan in Patients With Focal Segmental Glomerulosclerosis (FSGS) Without Nephrotic Syndrome in thePhase 3 DUPLEX Trial

Page 1 / 1 100%
Loading...